Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction

British Journal of Clinical Pharmacology

Volumn 53, Issue 3, 2002, Pages 232-237

  Stass, H ^a   Kubitza, D ^a   Halabi, A ^b   Delesen, H ^a  

^a BAYER AG   (Germany)

^b Clin Pharma Research AG (CPR)   (Germany)

Author keywords

Moxifioxacin; Pharmacokinetics; Renal impairment

Indexed keywords

CREATINE; GLUCURONIDE; MOXIFLOXACIN; SULFONIC ACID DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DISEASE SEVERITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HEADACHE; HUMAN; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; MEAN RESIDENCE TIME; NAUSEA; PATIENT MONITORING; PRIORITY JOURNAL; URINARY EXCRETION;

ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLUOROQUINOLONES; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; QUINOLINES;

EID: 0036124904     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01557.x     Document Type: Article

References (19)

1. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone
2. BAY 12-8309, a new 8-methoxyquinolone: in vitro activity against clinically important anaerobes
3. Susceptibility to BAY 12-8039 of pneumococci and staphylococci with varying levels of ciprofloxacin restistance
4. BAY 12-8039, a new 8-methoxy-quinolone, pharmacokinetics, safety and tolerability of single ascending intravenous doses in healthy male volunteers
5. Pharmacokinetics, safety and tolerability of ascending single doses ofmoxifloxacin, a new 8-methoxy quinolone administered to healthy subjects
6. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfuoroquinolone, after repeated oral administration
7. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man
8. 2-antagonists on the absorption of moxifloxacin after oral administration of a 400 mg dose to healthy volunteers
9. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers
10. The effect of food on the oral bioavailability of moxifloxacin in healthy male volunteers
11. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers
12. Moxifloxacin - Review of clinical pharmacokinetics: Distribution and tissue penetration
13. Interaction profile
14. Effect of probenecid on the kinetics of a single 400 mg dose in healthy male volunteers
15. No dose adjustments are needed for renally impaired patients receiving oral BAY 12-8039
16. Determination of BAY 12-8039, a new 8-methoxy-quinolone, in human body fluids by HPLC with fluorescence detection using on column focusing
17. Pooled analysis of pharmacokinetics, safety and tolerability of single oral 400 mg moxifloxacin doses in patietns with mild and moderate liver cirrhosis